Abcellera Biologics Inc
$ 9.34
34.78%
10 Aug - close price
- Market Cap 2,116,251,000 USD
- Current Price $ 9.34
- High / Low $ 10.01 / 8.40
- Stock P/E N/A
- Book Value 3.22
- EPS -0.54
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.15 %
- 52 Week High 8.44
- 52 Week Low 2.75
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$10.62
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-11 | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 |
| Reported EPS | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 | -0.1 |
| Estimated EPS | -0.17 | -0.2 | -0.144 | -0.16 | -0.17 | -0.14 | -0.1471 | -0.13 | -0.14 | -0.16 | -0.12 | -0.13 |
| Surprise | -0.01 | 0.06 | 0.114 | -0.03 | 0.05 | -0.01 | 0.0271 | -0.04 | 0.01 | 0.02 | -0.04 | 0.03 |
| Surprise Percentage | -5.8824% | 30% | 79.1667% | -18.75% | 29.4118% | -7.1429% | 18.4228% | -30.7692% | 7.1429% | 12.5% | -33.3333% | 23.0769% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-08-10 15:14:13
AbCellera Biologics (NASDAQ:ABCL) experienced unusually high options trading volume, with investors purchasing 16,666 call options, a 151% increase over the average. The company's shares surged by $2.37 to $9.30 on heavy trading volume, despite missing analyst expectations for both earnings and revenue in its latest quarter. Analysts have a "Moderate Buy" consensus rating with an average price target of $9.40, following recent upgrades and downgrades.
2026-08-10 13:42:13
Abcellera Biologics Inc. (ABCL) reached a 52-week high of $8.79, reflecting a 63% total return over the past year and 119% over six months. Despite this, an InvestingPro analysis suggests the stock may be overvalued. The company also announced positive Phase 2 clinical trial results for ABCL635, a menopause treatment, despite missing Q2 2026 financial expectations.
2026-08-10 13:42:13
Abcellera Biologics (ABCL) stock surged over 30% in pre-open trading after its antibody, ABCL 635, met the primary efficacy endpoint in a Phase 2 clinical trial for menopausal hot flashes, showing an 83% reduction in frequency. This clinical success, combined with strong analyst conviction and a robust balance sheet, led to an outsized market reaction despite broader market declines. The company's performance highlights its pipeline value and commercial potential in women's health.
2026-08-10 12:42:13
AbCellera Biologics Inc. (ABCL) stock is climbing due to a new collaboration with Vertex Pharmaceuticals worth $28 million upfront, and the anticipation of top-line Phase 2 data for its drug ABCL635, expected today. Despite recent misses on Q2 earnings and revenue, the company's strong balance sheet with over $504.7 million in cash and short-term investments, combined with analyst upgrades, positions it as a high-volatility, AI-biotech play with significant catalysts. Traders are focused on the upcoming data release and the company's transition to a platform-plus-pipeline model, validating its technology through big-pharma partnerships.
2026-08-10 12:42:13
AbCellera Biologics announced positive top-line results from its Phase II trial of ABCL-635, a non-hormonal treatment for menopausal hot flashes. The study showed an 83% reduction in moderate-to-severe hot flashes, along with improvements in symptom severity and sleep disturbance, and a favorable tolerability profile. The company is evaluating Phase III options, including a potential head-to-head study against existing treatments.
2026-08-10 11:42:13
AbCellera Biologics Inc. (ABCL) stock surged over 24% due to strong optimism surrounding its antibody discovery platform, a new collaboration with Vertex Pharmaceuticals, and upcoming Phase 2 data for ABCL635. The Vertex deal provides $28 million upfront, with potential milestones and royalties, validating ABCL's T-cell engager technology. Despite a Q2 earnings miss, the company boasts a strong balance sheet and analyst upgrades, positioning it as a high-volatility trading opportunity driven by AI-enabled drug discovery and a maturing clinical pipeline.
